6-K
GSK plc (GSK)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2020
Commission File Number 001-15170
GlaxoSmithKline plc
(Translation of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 26 May 2020
| Name<br>of applicant: | GlaxoSmithKline<br>plc | |||
|---|---|---|---|---|
| Name of<br>scheme: | GlaxoSmithKline<br>plc 2009 Deferred Annual Bonus Plan | |||
| Period<br>of return: | From: | 1<br>November 2019 | To: | 30<br>April 2020 |
| Balance<br>of unallotted securities under scheme(s) from previous<br>return: | 153,724 | |||
| Plus: The amount by which the block scheme(s) has<br>been increased since the date of the last return (if any increase<br>has been applied for): | 370,000 | |||
| Less: Number of securities issued/allotted under<br>scheme(s) during period (see LR3.5.7G): | 388,348 | |||
| Equals: Balance under scheme(s) not yet<br>issued/allotted at end of period: | 135,376 | |||
| Name of<br>contact: | Victoria<br>Whyte | |||
| --- | --- | |||
| Telephone<br>number of contact: | 020<br>8047 5000 |
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 26 May 2020
| Name<br>of applicant: | GlaxoSmithKline<br>plc | |||
|---|---|---|---|---|
| Name of<br>scheme: | GlaxoSmithKline<br>2009 Share Option Plan - Ordinary Shares | |||
| Period<br>of return: | From: | 1<br>November 2019 | To: | 30<br>April 2020 |
| Balance<br>of unallotted securities under scheme(s) from previous<br>return: | 835,095 | |||
| Plus: The amount by which the block scheme(s) has<br>been increased since the date of the last return (if any increase<br>has been applied for): | 0 | |||
| Less: Number of securities issued/allotted under<br>scheme(s) during period (see LR3.5.7G): | 581,004 | |||
| Equals: Balance under scheme(s) not yet<br>issued/allotted at end of period: | 254,091 | |||
| Name of<br>contact: | Victoria<br>Whyte | |||
| --- | --- | |||
| Telephone<br>number of contact: | 020<br>8047 5000 |
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 26 May 2020
| Name<br>of applicant: | GlaxoSmithKline<br>plc | |||
|---|---|---|---|---|
| Name of<br>scheme: | GlaxoSmithKline<br>2009 Share Option Plan - ADS | |||
| Period<br>of return: | From: | 1<br>November 2019 | To: | 30<br>April 2020 |
| Balance<br>of unallotted securities under scheme(s) from previous<br>return: | 5,391,416 | |||
| Plus: The amount by which the block scheme(s) has<br>been increased since the date of the last return (if any increase<br>has been applied for): | 0 | |||
| Less: Number of securities issued/allotted under<br>scheme(s) during period (see LR3.5.7G): | 698,736 | |||
| Equals: Balance under scheme(s) not yet<br>issued/allotted at end of period: | 4,692,680 | |||
| Name of<br>contact: | Victoria<br>Whyte | |||
| --- | --- | |||
| Telephone<br>number of contact: | 020<br>8047 5000 |
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 26 May 2020
| Name<br>of applicant: | GlaxoSmithKline<br>plc | |||
|---|---|---|---|---|
| Name of<br>scheme: | GlaxoSmithKline<br>plc Share Save Plan 2012 | |||
| Period<br>of return: | From: | 1<br>November 2019 | To: | 30<br>April 2020 |
| Balance<br>of unallotted securities under scheme(s) from previous<br>return: | 2,145,812 | |||
| Plus: The amount by which the block scheme(s) has<br>been increased since the date of the last return (if any increase<br>has been applied for): | 0 | |||
| Less: Number of securities issued/allotted under<br>scheme(s) during period (see LR3.5.7G): | 698,407 | |||
| Equals: Balance under scheme(s) not yet<br>issued/allotted at end of period: | 1,447,405 | |||
| Name of<br>contact: | Victoria<br>Whyte | |||
| --- | --- | |||
| Telephone<br>number of contact: | 020<br>8047 5000 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GlaxoSmithKline plc | |
|---|---|
| (Registrant) | |
| Date: May<br>26, 2020 | |
| By:/s/ VICTORIA<br>WHYTE<br><br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GlaxoSmithKline plc |